Psylo, Inc. is a biotechnology company focused on the discovery and development of next-generation neuroplastogens to treat psychiatric and neurological conditions. The company leverages medicinal chemistry and pharmacology to engineer safer, non-hallucinogenic psychedelic-inspired therapeutics. Its research and drug development efforts primarily serve patients suffering from treatment-resistant mental health disorders.
Subscribe to see Psylo, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Psylo, Inc. is a biotechnology company headquartered in Australia. Its most recent funding round raised $5M in May 2024. Xcout tracks 10 named people at Psylo, Inc., including Joshua Ismin (Chief Executive Officer, Cofounder).
As of 16 November 2026. Source: Xcout Intel.
4 more named people on record for Psylo, Inc., with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $5M | — | |
| Seed | $8M | 5 named | |
| Seed | $1.1M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A funding-flow diagram of the 8 named investors across 2 rounds: who backed which round, who led it, and who came back for the next one.
Sign in to see it, or subscribe for the full funding history →
A few of Psylo, Inc.'s closest competitors — see the full list of competitors and alternatives →
Lykos Therapeutics is a biotechnology company developing psychedelic-assisted therapies, particularly MDMA-assisted therapy for post-traumatic stress disorder (PTSD). It works with clinicians and researchers to advance regulated treatments for people with PTSD and related mental-health conditions.
Beckley Psytech is a UK-based clinical-stage biotechnology company developing psychedelic medicines for psychiatric and neurological disorders. Its programs have included BPL-003, an intranasal formulation of 5-MeO-DMT, intended for conditions such as treatment-resistant depression and alcohol use disorder.
Synendos Therapeutics is a clinical-stage biopharmaceutical and neuroscience company focused on developing a novel class of small molecules to treat psychiatric and neurological disorders.
Gilgamesh Pharma Inc. is a clinical-stage neuroscience company that develops novel chemical entities to treat psychiatric diseases, aiming to move beyond symptom management toward rapid-acting and durable therapies. The company utilizes an AI-powered discovery platform and medicinal chemistry to create precision therapies targeting conditions such as depression, anxiety, addiction, and schizophrenia.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
FIVE DISCOVERY Corp is a biotechnology company that develops non-hallucinogenic neuroplastogen therapeutics designed to repair and stabilize dysfunctional neural circuits. The company serves patients suffering from neurodegenerative conditions and brain injuries, including Alzheimer's disease, Parkinson's disease, and traumatic brain injury.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Psylo, Inc.? Suggest a correction · Work at Psylo, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.